Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
- Korean Cancer Study Group (KCSG)
- Seoul National University
- Yonsei University
- Ajou University
- National Cancer Center Korea
- Ewha Womans University
- Gachon University
- Inha University
- Chung-Ang University
- Soonchunhyang University
- Wonju Severance Christian Hospital
- University of Ulsan
Research output: Contribution to journal › Article › peer-review
117
Link opens in a new tab
Scopus
citations